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Background: Chronic cough and sputum production (chronic mucus hypersecretion) is a poorly
described clinical feature of asthma. Our objective was to identify clinical, immunological and
computed tomography (CT) measures of airway wall dimensions associated with these symp-
toms in smokers and never smokers with asthma.
Methods: Cross-sectional data was analysed from 120 smokers and never smokers with asthma.
Participants with and without a history of chronic mucus hypersecretion were compared for
clinical outcomes, sputum differential cell counts and CT measures of airway dimensions (wall
thickness, luminal area and percent wall area).
Results: Chronic mucus hypersecretion occurred in a higher proportion of smokers with asthma
(56%) than never smokers with asthma (20%), (p < 0.001) and the proportion of patients with
these symptoms increased with asthma severity (pZ 0.003). Smokers with asthma and chronic
mucus hypersecretion had worse current clinical control than smokers without those symptoms
[ACQ score 2.3 versus 1.6, p Z 0.002]. A greater proportion of never smokers with chronic
mucus hypersecretion required short courses of oral corticosteroids in the last year (58% versus
19%, pZ 0.011). Sputum neutrophil and eosinophil counts were similar in asthma patients with
or without chronic mucus hypersecretion. Of those with severe asthma and chronic mucusInfection, Immunity & Inflammation, University of Glasgow and Respiratory Medicine, Gartnavel
cotland, UK. Tel.: þ44 141 211 1673; fax: þ44 141 211 3464.
gow.ac.uk (N.C. Thomson).
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3.07.017
1502 N.C. Thomson et al.hypersecretion, a CT measure of airway lumen area was reduced in smokers compared to never
smokers (11.4 mm2 versus 18.4 mm2; p Z 0.017).
Conclusions: Chronic mucus hypersecretion occurs frequently in adults with stable asthma,
particularly in smokers with severe disease and is associated with worse current clinical control
in smokers and more exacerbations in never smokers.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic cough and sputum production due to airway mucus
hypersecretion is an important component of several
airway diseases including chronic obstructive pulmonary
disease (COPD) and asthma. Cigarette smoking is one of the
strongest risk factors for chronic bronchitis, also termed
chronic mucus hypersecretion, in individuals with and
without airflow limitation [1]. Chronic mucus hypersecre-
tion develops in asthma [2e5], at least in part, due to the
pro-inflammatory effects on airway epithelial glands of the
T-helper type 2 (Th2) cytokines interleukin (IL)-9 and IL-13,
as well as IL-1b and tumour necrosis factor (TNF)-a [6].
The prevalence rates for chronic bronchitis vary be-
tween studies, due to differences in the definitions used
and in the populations studied, but overall a consistent
picture emerges of higher rates in airway disease and with
cigarette smoking [5,7]. A systematic review of 38 studies
reported a prevalence rate for chronic bronchitis of 6.4% in
the general population [8] and with increased rates in
smokers without airflow obstruction [2,9]. Higher rates are
found in patients with COPD compared to smokers without
COPD, with prevalence rates ranging from 27% [10] to over
70% [11e13]. There is more limited information on the
prevalence rates for chronic cough and sputum production
in asthma [2e5,14]. The Copenhagen City Heart Study and
the European Community Respiratory Health (ECRH) survey
reported prevalence rates of 39% and 42% respectively in
non-smokers with asthma and with higher rates in smokers
with asthma [2,14].
Chronic bronchitis in COPD has been associated with
worse clinical outcomes [7,10] and increased mortality [9].
Less is known about the clinical features of patients with
asthma who give a history of chronic mucus hypersecretion
compared to those without these symptoms. Chronic mucus
hypersecretion is associated with a significantly greater
decline in FEV1 among smokers with asthma [2], with more
severe disease [3] and with chronic persistent airflow
obstruction in non-smokers with asthma [4]. The presence
of excessive airway mucus in asthma may also contribute to
exacerbations and fatal attacks of asthma [15].
Taken together, these findings indicate that whilst
chronic mucus hypersecretion is known to occur in asthma
and that it may play a role in disease outcomes, the re-
lationships between chronic mucus hypersecretion in
smokers and never smokers with asthma with clinical, lung
function, immunological outcomes and computed tomog-
raphy (CT) airway dimensions are unknown. We wished to
test the hypothesis that clinical outcomes are worse and/or
that inflammatory biomarkers and CT measures of airway
dimensions differ, in patients with asthma who give ahistory of chronic mucus hypersecretion and that these
outcomes are also influenced by smoking status and disease
severity. We undertook an analysis of 120 subjects with
asthma (smokers and never smokers) of differing severity
to test this hypothesis, by examining outcomes in those
with symptoms of chronic cough and sputum production
compared to those without these symptoms.
Methods
Subjects and study design
A cross sectional study was performed in subjects with
asthma recruited to the Glasgow COPD and Asthma
Biomarker study [16]. Clinical, physiological, induced
sputum cell counts and CT measurements were performed.
Participants were recruited with mild, moderate and severe
persistent asthma (GINA classification) [17], (both current
smokers and never-smokers):
Age range 18e75 years and duration of asthma 6
months; Symptoms of episodic wheezing, chest tightness
and/or dyspnoea; Objective confirmation by airway hy-
peractivity determined by a positive methacholine chal-
lenge or where this was not safe (when FEV1 < 60%
predicted), by evidence of airflow variability with a 12%
and 200 ml increase in FEV1 following nebulised salbutamol
2.5 mg. The West Glasgow Research Ethics Committee
approved the study and all patients gave written informed
consent.
Patients had 3 study visits. At the first visit, the medical
history was obtained and a methacholine challenge per-
formed. At the second visit, one week later, spirometry and
reversibility plus sputum induction were performed and
asthma questionnaires completed. The third visit, a month
later, was to assess reproducibility of sputum measure-
ments. The CT scan and static lung volumes/diffusion ca-
pacity measurements were performed on visit 2 or 3. The
participants were recruited over an 18 month period.
Measurements
Questionnaires
A history of chronic mucus hypersecretion was based on the
question:
‘Do you have a history of persistent sputum >3 months
per year’. Asthma control questionnaire (ACQ) score [18]
was also obtained. Information was obtained from partici-
pants on the number of hospital admissions, accident and
emergency visits and emergency oral corticosteroid use in
the last year.
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Spirometry was performed according to ATS guidelines [19]
and airway hyper-responsiveness to methacholine was
measured [20]. Lung volumes and diffusing capacity for
carbon monoxide (DLco) were performed using the body
box technique (Zan500 Body Plethysmography, nSpire
Health Limited, Hertford, UK).
Sputum induction
Performed using hypertonic saline and processed as previ-
ously described [16]. Samples with cell viability <40% or
epithelial squamous cells >80% were discarded.
CT scan of the chest
Scans were performed at full inspiration using 16 slice
Brightspeed and 64 slice Lightspeed (GE CT scanner, Mil-
waukee, Wisconsin, USA) with the following parameters:
120 KV, 100 mAs, collimation 1 mm, reconstruction slice
thickness 0.65 mm, reconstruction slice separation 0.5 mm,
pitch of 1 and the data was reconstructed with a CHST fil-
ter. All scans were evaluated centrally at the University of
Edinburgh. Airway dimensions were measured using soft-
ware previously described [21], which plots an airway path
from which airway profiles were generated on cross-
sections orthogonal to this airway path. Airway di-
mensions were measured at 1 mm intervals in the right
lower lobe posterior basal segmental bronchus (designated
RB10) from airway generation 3e6 using the full width at
half maximum (FWHM) technique. The airway lumen
diameter and airway wall thickness were measured and the
percentage wall area (% WA) was calculated as (outer area
of airway  lumen area)/outer area of airway  100.Statistical analysis
The study population was divided into those with and
without a history of chronic mucus hypersecretion. Data
were analysed using R version 2.15 [22]. Continuous vari-
ables were summarized as median (inter-quartile range).
Their comparison between different patient groups was by
t-test or one-way analysis of variance for approximatelyTable 1 Demographics and clinical baseline characteristics.
Asthm
Neve
Number 59
Age (years) 48.2
Sex (male) 23 (3
Disease duration (years) 21.0
FEV1% predicted pre-bronchodilator 79.0
FEV1% predicted post-bronchodilator 91.0
FEV1/FVC post-bronchodilator 78.0
Pack years smoked e
DLCO% predicted COHb 86 (8
Beclometasone equivalent dose of inhaled steroid 800 (
Data depicted as Median (IQR) unless otherwise specified. Boldface p
Abbreviations: FEV1 Z forced expired volume in one second, FVC Z
carbon monoxide, corrected for haemoglobin and carboxyhaemoglobnormally distributed variables and by Wilcoxon tests or
KruskaleWallis tests for other variables. Categorical vari-
ables were summarized by their observed frequencies and
percentages within the participant subsets, and were
compared using Fisher’s exact probability tests including
the Freeman-Halton extension for variables with more than
2 categories.
Results
Patient characteristics
Smokers with asthma and never smokers with asthma were
similar for age, duration of asthma and dose of inhaled
corticosteroid (Table 1). Additional therapies such as long-
acting beta2-agonists, leukotriene receptor antagonists or
oral prednisolone were similar between severity groups.
Smokers with asthma had a slightly lower median FEV1/FVC
ratio (median FEV1/FVC ratio 72% versus 78%, p Z 0.029)
and lower diffusing capacity (77% versus 86%, p < 0.001)
than never smokers with asthma.
Prevalence of chronic cough and sputum
production
Chronic mucus hypersecretion was reported by a higher
proportion of smokers with asthma (56%) compared with
the never smokers with asthma (20%), (p < 0.001). The
proportion of patients with chronic mucus hypersecretion
increased with asthma severity (p Z 0.003); in both
smokers (p Z 0.012) and never smokers (p Z 0.045)
[Fig. 1].
Clinical characteristics of participants according to
the presence of chronic mucus hypersecretion
Smokers with asthma and chronic mucus hypersecretion
had higher ACQ scores (2.29 versus 1.57, p Z 0.002), but
were similar to smokers with asthma without this symptom
for other clinical characteristics (Table 2, Fig. 2). A greatera
r smoker Smoker p-Value
61
(39.8, 53.9) 47.5 (42.0, 52.8) p Z 0.941
9.0%) 29 (47.5%) p Z 0.363
(9.5, 38.0) 20.0 (10.0, 32.0) p Z 0.486
(70.0, 91.0) 78.0 (58.0, 93.2) p Z 0.599
(79.0, 98.0) 84.0 (70.5, 102.0) p Z 0.429
(69.0, 83.0) 72.5 (66.8, 79.2) p Z 0.029
33.0 (22.0, 52.0) e
0, 93) 77 (66, 86) p Z 0.001
400, 1000) 800 (700, 1000) p Z 0.384
values indicate p < 0.05.
forced vital capacity, DLco% predicted Z Diffusing capacity for
in (COHb) as a percentage of the predicted value.
Figure 1 Proportion of patients with asthma of different
disease severity and smoking status with a history of chronic
mucus hypersecretion (CMH). The proportion of patients with
cough and sputum production increased with asthma severity
(p Z 0.003); in both smokers (p Z 0.012) and never smokers
(p Z 0.045).
Table 2 Clinical and lung function and imaging outcomes in
presence of chronic cough and sputum production.
Never smokers with asthma
CMHþ (n Z 12) CMH (n Z 47) p
Age (years) 47.7 (42.1, 56.1) 48.2 (37.5, 53.5) p
Gender (male) 4 (33.3%) 19 (40.4%) p
Disease duration (years) 22.0 (15.0, 27.0) 21.0 (9.0, 42.0) p
ACQ score 1.71 (1.00, 2.58) 1.00 (0.57, 1.68) p
BMI kg/m2 30.4 (25.5, 36.4) 28.3 (25.3, 32.5) p
FEV1% predicted pre
bronchodilator
79.0 (62.0, 85.5) 81.0 (71.2, 91.8) p
FEV1% predicted
post bronchodilator
91.0 (78.5, 97.0) 90.0 (79.2, 98.0) p
Pack years smoked e e e
DLCO% predicted COHb 84.0 (73.5, 91.5) 86.0 (81.0, 93.0) p
Beclometasone
equivalent dose of
inhaled corticosteroids
(mg)
1000 (600, 1600) 800 (400, 800) p
Hospitalisation or A&E
visits for asthma in
the past year
2 (16.7%) 2 (4.3%) p
Emergency oral steroid
use in last 1 year
7 (58.3%) 9 (19.1%) p
History suggestive of
rhino-sinusitis
6 (50.0%) 15 (31.9%) p
History suggestive of
allergic rhinitis
8 (66.7%) 25 (53.2%) p
Data depicted as median (IQR) or for bottom four rows as number (p
* p-Value for comparison between never smokers with asthma
CMHZ chronic mucus hypersecretion (chronic cough and sputum prod
mass index; FEV1 Z forced expired volume in one second, DLco %
monoxide, corrected for haemoglobin and carboxyhaemoglobin; A&E
1504 N.C. Thomson et al.proportion of never smokers with asthma and chronic
mucus hypersecretion required emergency short courses of
oral corticosteroids in the last year (58.3% versus 19.1%,
pZ 0.011), but were similar to never smokers with asthma
without this symptom for all other clinical characteristics
(Table 2, Fig. 3). Smokers with severe asthma with chronic
mucus hypersecretion compared to never smokers with
severe asthma with these symptoms had higher ACQ scores
(2.9 versus 1.9, p < 0.044), but did not differ significantly in
age, duration of disease, pre-and post-bronchodilator FEV1,
and inhaled corticosteroid dose (Table 4).Sputum cell counts of participants according to the
presence of cough and sputum production
The percentage of induced sputum neutrophil and eosino-
phils were similar in patients with chronic mucus hyperse-
cretion to those without these symptoms in smokers with
asthma and never smokers with asthma (Table 3). Smokers
with asthma with chronic mucus hypersecretion compared
to never smokers with similar symptoms did not differ in the
percentage of induced sputum neutrophil or eosinophil cell
counts; similar results were found in subjects with severe
disease (Table 4).never-smokers and smokers with asthma according to the
Smokers with asthma
-Value CMHþ (n Z 34) CMH (n Z 27) p-Value
Z 0.651 48.4 (42.1, 53.2) 45.6 (41.5, 51.5) p Z 0.796
Z 0.749 17 (50.0%) 12 (44.4%) p Z 0.797
Z 0.325 15.5 (10.0, 36.0) 20.0 (11.0, 31.0) p Z 0.873
Z 0.115 2.29 (1.57, 3.00) 1.57 (1.21, 1.97) p Z 0.002
Z 0.481 26.0 (23.4, 30.2) 25.7 (22.2, 29.5) p Z 0.528
Z 0.310 78.0 (58.0, 93.0) 77.0 (65.0, 93.5) p Z 0.692
Z 0.629 85.0 (69.0, 99.0) 83.0 (71.0, 102.0) p Z 0.953
31.0 (23.0, 58.0) 34.0 (19.0, 50.5) p Z 0.805
Z 0.214 76.5 (61.0, 86.0) 77.0 (69.0, 84.0) p Z 0.608
Z 0.112 800 (800, 1000) 800 (400, 1000) p Z 0.188
Z 0.181 3 (8.8%) 0 (0.0%) p Z 0.248
Z 0.011 10 (29.4%) 4 (14.8%) p Z 0.228
Z 0.315 10 (29.4%) 5 (18.5%) p Z 0.382
Z 0.521 18 (52.9%) 13 (48.1%) p Z 0.799
ercent). Boldface p values indicate p < 0.05.
and CMH and smokers with asthma and CMH. Abbreviations:
uction); ACQZ asthma control questionnaire score; BMIZ body
pred Z Diffusing capacity for the lungs measured using carbon
Z accident and emergency.
Figure 2 Asthma control questionnaire (ACQ) score in never-
smokers with asthma and smokers with asthma according to
the presence of chronic mucus hypersecretion. Smokers with
asthma and chronic mucus hypersecretion had higher ACQ
scores (2.3 versus 1.6, p Z 0.002). Abbreviations: CMH,
chronic mucus hypersecretion; ve, CMH absent; þve, CMH
present.
Chronic cough and sputum production in asthma 1505CT imaging measures in participants according to
the presence of cough and sputum production
CT measures of airway dimensions (RB10 wall thickness;
RB10 lumen area; RB10% wall area) were similar between
patient groups with and without chronic mucus hyperse-
cretion (Table 2). RB10 lumen area was reduced in smokers
with severe asthma with chronic mucus hypersecretion
compared to never smokers with severe asthma (11.4 mm2
(8.9, 13.0) versus 18.4 mm2 (13.7, 23.0), p Z 0.017) with
chronic mucus hypersecretion (Table 4).
Discussion
In the study we determined whether clinical outcomes are
worse and/or that sputum cell counts or CT measures ofFigure 3 Emergency short courses of oral corticosteroids in
the last year in never-smokers with asthma and smokers with
asthma according to the presence of chronic mucus hyperse-
cretion. A greater proportion of never smokers with asthma
and chronic mucus hypersecretion required emergency short
courses of oral corticosteroids in the last year (58.3% versus
19.1%, p Z 0.011). Abbreviations: CMH, chronic mucus
hypersecretion; ve, CMH absent; þve, CMH present.airway dimensions differ, in patients with asthma who give
a history of chronic cough and sputum production compared
to those without these symptoms. The main findings were
that chronic mucus hypersecretion is a common symptom in
adults with stable asthma, particularly in smokers and in
patients with severe disease. Chronic mucus hypersecretion
was associated with worse current clinical control in
smokers with asthma and a greater number of short courses
of oral steroids in never smokers with asthma. Sputum cell
counts did not differ significantly in the asthmatic partici-
pants in relation to symptoms of chronic mucus hyperse-
cretion. CT lumen was reduced in smokers with severe
asthma with chronic mucus hypersecretion compared to
never smokers with severe asthma.
The definition of chronic mucus hypersecretion in some
surveys required the presence of daily productive cough for
at least three consecutive months for more than two suc-
cessive years, whereas in others the presence of chronic
cough and phlegm production for more than 1 year was
sufficient [23]. In our study the diagnosis of chronic mucus
hypersecretion omitted reference to ‘2 or more years’ and
might have overestimated the prevalence of chronic cough
and sputum production. In support of our findings, when
comparisons are made between groups, the same question
was used in all participants. In the Copenhagen City Heart
Study, 39% of the non-smokers with asthma (mean age of 52
years) gave a history of chronic mucus hypersecretion [2], a
prevalence rate similar to the never smokers with severe
asthma in our study (36.4%), but a much higher proportion
than reported in patients with mild or moderate disease
(5.3% and 16.7% respectively). We found higher rates of
chronic mucus hypersecretion in smokers with asthma in all
categories of disease severity compared to never smokers
with asthma, but particularly in the severe group (78.3%).
Overall these results indicate that chronic mucus hyperse-
cretion is a common clinical symptom in chronic persistent
asthma, particularly in smokers.
Smokers with asthma with chronic mucus hypersecretion
had higher ACQ scores than smokers without these symp-
toms. The ACQ-6 score comprises 6 questions on different
aspects of asthma control and although no specific question
enquires about cough and sputum production, these
symptoms impacted on the overall score. Smokers with
asthma are known to have worse ACQ scores than never
smokers with asthma [24] and possibly a history of chronic
mucus hypersecretion adversely effects the perception of
symptoms in this sub-group of smokers, particularly in those
with severe disease. A similar effect on ACQ scores was not
seen in the never smokers with asthma including patients
with severe asthma. A greater proportion of never smokers
with chronic mucus hypersecretion required emergency
short courses of oral corticosteroids in the last year sug-
gesting that these symptoms are associated with increased
rates of exacerbation of asthma. In the general population,
smokers that develop chronic bronchitis are at increased
risk of developing COPD and increased mortality [9]. In
asthma, chronic mucus hypersecretion is associated with a
significantly greater decline in FEV1 among smokers [2] and
with chronic persistent airflow obstruction in non-smokers
[4].
Airway mucin (MUC) is primarily produced by airway
goblet cells and in asthma MUC5AC is the predominant
Table 3 Induced sputum cell counts and computed tomography (CT) measures in never smokers and smokers with asthma
according to the presence of chronic cough and sputum production.
Never smokers with asthma Smokers with asthma
CMHþ (n Z 12) CMH (n Z 47) p-Value CMHþ (n Z 34) CMH (n Z 27) p-Value
Sputum cell counts
Total cell count (104/mL) 610 (541, 822) 662 (508, 866) p Z 0.745 583 (533, 740) 574 (473, 727) p Z 0.576
Neutrophils (%) 41.2 (24.5, 73.5) 49.8 (28.0, 63.6) p Z 0.920 50.0 (29.5, 69.5) 65.0 (43.2, 72.0) p Z 0.132
Eosinophils (%) 1.00 (0.25, 1.50) 0.75 (0.00, 2.25) p Z 0.619 0.50 (0.00, 1.50) 0.50 (0.25, 2.50) p Z 0.517
Macrophages (%) 24.0 (19.6, 50.8) 33.8 (16.6, 52.9) p Z 0.724 24.5 (18.0, 42.5) 23.0 (13.5, 37.0) p Z 0.672
CT imaging
RB10 wall thickness (mm) 1.61 (1.50, 1.73) 1.50 (1.43, 1.77) p Z 0.372 1.66 (1.60, 1.78) 1.65 (1.54, 1.80) p Z 0.390
RB10 lumen area mm2 19.4 (13.7, 22.7) 18.2 (12.4, 21.7) p Z 0.737 13.0 (9.3, 17.9) 15.5 (11.2, 18.9) p Z 0.692
RB10% wall area 64.9 (60.8, 67.4) 63.9 (60.0, 68.7) p Z 0.989 69.8 (62.3, 76.0) 68.6 (62.9, 73.2) p Z 0.442
Data depicted as median (IQR). Boldface p values indicate p < 0.05.Abbreviations: CMHZ chronic mucus hypersecretion (chronic cough
and sputum production); CT Z Computed tomography; mm Z millimetres; RB10 Z right bronchial division 10.
1506 N.C. Thomson et al.mucin gene increased in the epithelium [25]. The effects of
corticosteroids in suppressing MUC5AC gene expression in
human bronchial epithelial cells is histone-deacetylase-2
(HDAC2) dependent [26] and as reduced HDAC2 activity is
implicated in causing corticosteroid insensitivity in smokers
with asthma and in severe asthma [27], it is possible that
this mechanism accounts for the high prevalence of chronic
mucus hypersecretion in these groups of patients. Smokers
with asthma have more goblet cells and mucus-positive
epithelium than either ex-smokers or never-smokers with
asthma [28], likely due to the effects of tobacco smoke as
well as increased release of elastase from subepithelial
neutrophils [29], although in the present study theTable 4 Comparison of clinical, lung function, sputum cell cou
with severe asthma with a history of chronic cough and sputum p
Never smoker wit
severe asthma an
Number 8
Age (years) 44.9 (42.1, 52.3)
Gender (male) 4 (50.0%)
Disease duration (years) 22.0 (15.0, 30.8)
ACQ score 1.9 (1.6, 2.6)
BMI kg/m2 26.1 (24.8, 38.8)
FEV1% predicted post bronchodilator 82.0 (61.5, 87.0)
Pack years smoked e
DLCO% COHb 84.0 (75.0, 91.5)
Beclometasone equivalent dose
of inhaled corticosteroids (mg)
1200 (800, 2250)
Sputum cell counts
Neutrophils (%) 49.5 (19.2, 78.6)
Eosinophils (%) 1.50 (1.12, 3.75)
CT imaging
RB10 wall thickness (mm) 1.60 (1.50, 1.73)
RB10 lumen area mm2 18.4 (13.7, 23.0)
RB10% wall area 64.0 (60.8, 66.9)
Data depicted as median (IQR). Boldface p values indicate p < 0.05.
Abbreviations: CMH Z chronic mucus hypersecretion (chronic cough
second, DLco% pred Z Diffusing capacity for the lungs measured u
yhaemoglobin; CT Z Computed tomography; mm Z millimetres; RB1proportion of induced sputum neutrophils or eosinophils
was similar in smokers or never smokers with asthma irre-
spective of the presence or absence of a history of chronic
cough and sputum production.
Here we found that CT measures of airway dimensions
(RB10 wall thickness; RB10 lumen area; RB10% wall area)
were similar between patients with or without a history of
chronic mucus hypersecretion in smokers and never
smokers with asthma. However airway lumen area was
reduced in smokers with severe asthma who gave a history
of chronic cough and sputum production compared to never
smokers with severe asthma with similar symptoms. The
difference in airway wall area was unlikely to be as a resultnts and CT measures outcome in never smokers and smokers
roduction.
h
d CMHþ
Smoker with severe
asthma and CMHþ
p Value
18
51.2 (43.2, 54.8) p Z 0.493
7 (38.9%) p Z 0.683
23.5 (14.2, 36.0) p Z 0.912
2.9 (2.3, 3.6) p Z 0.044
27.9 (23.9, 31.5) p Z 0.569
76.0 (69.0, 97.0) p Z 0.554
34.0 (23.8, 60.0)
67.0 (56.0, 84.0) p Z 0.077
1000 (800, 1900) p Z 0.591
48.5 (35.0, 66.2) p Z 0.931
1.00 (0.50, 2.50) p Z 0.367
1.68 (1.64, 1.85) p Z 0.380
11.4 (8.9, 13.0) p Z 0.017
74.3 (69.3, 76.5) p Z 0.106
and sputum production); FEV1 Z forced expired volume in one
sing carbon monoxide, corrected for haemoglobin and carbox-
0 Z right bronchial division 10.
Chronic cough and sputum production in asthma 1507of variations in bronchodilator use (unpublished data).
Lumen area can be influenced by mucus accumulation and
this may occur to a greater extent in smokers with severe
asthma.
There are several potential limitations to our findings.
The cross-sectional study design used did not allow us to
determine whether the prevalence of chronic mucus hy-
persecretion and the association between these symptoms
and clinical outcomes and CT measures in the asthma
groups varies over time. Potential inaccuracy of CT mea-
surements of airway measurements might exist as no
standardised methodology exists, however we used tech-
niques where reproducibility has been previously validated
[21]. Finally the main findings require to be confirmed in
large prospective studies of patients with asthma.
In conclusion, chronic cough and sputum production are
common symptoms in adults with chronic stable asthma,
particularly in smokers and patients with severe disease.
Chronic mucus hypersecretion is likely to contribute to poor
current symptom control in smokers with asthma and to
increased exacerbations rates in never smokers with
asthma.
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